Eje microbioma-inmuno-cutáneo y neuro-metabólico en enfermedades inflamatorias crónicas complejas: cohorte transcontinental y algoritmo de predicción terapéutica
Salud Medicina e Innovación Journal · 2026
DOI: 10.70577/4sn10c26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Salud Medicina e Innovación Journal, 2026. Verfasst von Johanna Nathaly Hidalgo Guevara und 4 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Introduction
Complex chronic inflammatory diseases (CCIDs), including psoriasis, inflammatory bowel disease (IBD), atopic dermatitis, and neuropsychiatric disorders, exhibit high comorbidity and share pathophysiological mechanisms mediated by the gut-brain-skin axis (Hawkins et al., 2025; Pearson et al., 2025). Gut microbial dysbiosis, characterized by depletion of short-chain fatty acid (SCFA)-producing taxa and enrichment of pro-inflammatory taxa, emerges as a unifying factor in these conditions (Hawkins et al., 2025).
Objective
To synthesize the available evidence on the microbiome-immune-cutaneous and neuro-metabolic axis in CCIDs, and to evaluate the potential of therapeutic prediction algorithms based on multimodal phenotyping to guide personalized interventions. Methodology: Systematic review following PRISMA 2020 guidelines (Page et al., 2021). A systematic search was conducted in PubMed, LILACS, SciELO and Cochrane for studies published between 2020 and 2026 on the gut-brain-skin axis, multimodal phenotyping and predictive algorithms in CCIDs. Observational studies, technological developments and clinical trials were included. Quality was assessed using the adapted Newcastle-Ottawa scale (Wells et al., 2000).
Results
Eight relevant studies were identified. Evidence confirms that gut dysbiosis, characterized by reduction of Faecalibacterium, Roseburia and Eubacterium, and increase of pro-inflammatory taxa, is consistently associated with CCIDs and their neuropsychiatric comorbidities (Hawkins et al., 2025; Vestergaard et al., 2026). Multi-omics studies have demonstrated significant genetic correlations between IBD and psoriasis (ρ = 0.23-0.25) (Vestergaard et al., 2026). Microbiome-directed interventions, including probiotics, prebiotics and dietary modifications, have shown promising effects in reducing systemic inflammation and improving cutaneous and neuropsychiatric symptoms (Biazzo et al., 2026; Hawkins et al., 2025).
Conclusion
The microbiome-immune-cutaneous and neuro-metabolic axis represents an integrative paradigm for understanding the pathogenesis of CCIDs and their comorbidities. Therapeutic prediction algorithms based on multimodal phenotyping offer a promising pathway for precision medicine, enabling personalized selection of microbiome-directed interventions in the context of transcontinental cohorts.
Zitieren
APA
Guevara, J. N. H., Carrasco, J. A. A., Muso, J. P. C., Ponce, A. V. A., & Coronel, K. J. A. (2026). Eje microbioma-inmuno-cutáneo y neuro-metabólico en enfermedades inflamatorias crónicas complejas: cohorte transcontinental y algoritmo de predicción terapéutica. Salud Medicina e Innovación Journal. https://doi.org/10.70577/4sn10c26
Vancouver
Guevara JNH, Carrasco JAA, Muso JPC, Ponce AVA, Coronel KJA. Eje microbioma-inmuno-cutáneo y neuro-metabólico en enfermedades inflamatorias crónicas complejas: cohorte transcontinental y algoritmo de predicción terapéutica. Salud Medicina e Innovación Journal. 2026. doi:10.70577/4sn10c26
BibTeX
@article{Guevara2026,
author = {Guevara, Johanna Nathaly Hidalgo and Carrasco, Juan Andrés Armendáriz and Muso, Jenifer Pamela Cando and Ponce, Adriana Vanessa Alcivar and Coronel, Karen Joseline Achig},
title = {Eje microbioma-inmuno-cutáneo y neuro-metabólico en enfermedades inflamatorias crónicas complejas: cohorte transcontinental y algoritmo de predicción terapéutica},
journal = {Salud Medicina e Innovación Journal},
year = {2026},
doi = {10.70577/4sn10c26}
}
EUVIMED